FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1834341727> ?p ?o ?g. }

• W1834341727 abstract "Nerve growth factor plays a key role in the pathology of osteoarthritis (OA) related chronic pain. The aim of these studies was to evaluate the safety, tolerability, pharmacokinetics, and clinical response of AMG 403, a human anti-nerve growth factor monoclonal antibody, in healthy volunteers and subjects with knee OA.Two phase I, randomized, placebo-controlled, double-blind studies were conducted. The single-ascending dose study randomized healthy volunteers (n = 48) 3:1 to receive AMG 403 (1, 3, 10, or 30 mg intravenously; or 10 or 30 mg subcutaneously; n = 8 per group) or placebo. The multiple-ascending dose study randomized knee OA subjects (n = 18) 3:1 to receive AMG 403 (3, 10, or 20 mg subcutaneously once monthly for four doses) or placebo. Safety, tolerability, and pharmacokinetics (PK) were assessed for both studies. Patient's and physician's disease assessments and total WOMAC score were determined in knee OA subjects.AMG 403 appeared to be well-tolerated after single and multiple doses, except for subject-reported hyperesthesia, pain, and paresthesia (mild to moderate severity). These treatment-emergent neurosensory events showed evidence of reversibility and a possible dose-dependence. Three serious adverse events were reported in AMG 403 treated subjects, but were not considered treatment related. AMG 403 PK was linear with an estimated half-life of 19.6 to 25.8 days. After multiple doses, AMG 403 PK showed modest accumulation (≤2.4-fold increase) in systemic exposure. Knee OA diagnosis, body weight, and anti-drug antibody development did not appear to affect AMG 403 PK. Patient's and physician's disease assessments and total WOMAC score showed improvement in AMG 403 treated knee OA subjects compared with placebo.AMG 403 was generally safe and well-tolerated in both healthy volunteers and knee OA patients, and exhibited linear pharmacokinetics. Preliminary clinical efficacy was observed in knee OA subjects.ClinicalTrials.gov NCT02348879 . Registered 23 December 2014. Clintrials.gov NCT02318407 . Registered 2 December 2014." @default.
• W1834341727 created "2016-06-24" @default.
• W1834341727 creator A5011111764 @default.
• W1834341727 creator A5015608013 @default.
• W1834341727 creator A5036798090 @default.
• W1834341727 creator A5046991927 @default.
• W1834341727 creator A5061464184 @default.
• W1834341727 creator A5067414076 @default.
• W1834341727 creator A5076592943 @default.
• W1834341727 creator A5087679577 @default.
• W1834341727 date "2015-10-08" @default.
• W1834341727 modified "2023-10-04" @default.
• W1834341727 title "Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects" @default.
• W1834341727 cites W1549780609 @default.
• W1834341727 cites W1957937187 @default.
• W1834341727 cites W1965622444 @default.
• W1834341727 cites W1965665343 @default.
• W1834341727 cites W1978285583 @default.
• W1834341727 cites W1980716397 @default.
• W1834341727 cites W2004213014 @default.
• W1834341727 cites W2007511577 @default.
• W1834341727 cites W2008442706 @default.
• W1834341727 cites W2018762794 @default.
• W1834341727 cites W2019559069 @default.
• W1834341727 cites W2057093576 @default.
• W1834341727 cites W2059524959 @default.
• W1834341727 cites W2063851754 @default.
• W1834341727 cites W2067933166 @default.
• W1834341727 cites W2081338578 @default.
• W1834341727 cites W2089480099 @default.
• W1834341727 cites W2091349116 @default.
• W1834341727 cites W2094255752 @default.
• W1834341727 cites W2127382293 @default.
• W1834341727 cites W2133915381 @default.
• W1834341727 cites W2134905207 @default.
• W1834341727 cites W2135119721 @default.
• W1834341727 cites W2152271013 @default.
• W1834341727 doi "https://doi.org/10.1186/s13075-015-0797-9" @default.
• W1834341727 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4599327" @default.
• W1834341727 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26449617" @default.
• W1834341727 hasPublicationYear "2015" @default.
• W1834341727 type Work @default.
• W1834341727 sameAs 1834341727 @default.
• W1834341727 citedByCount "20" @default.
• W1834341727 countsByYear W18343417272016 @default.
• W1834341727 countsByYear W18343417272017 @default.
• W1834341727 countsByYear W18343417272018 @default.
• W1834341727 countsByYear W18343417272020 @default.
• W1834341727 countsByYear W18343417272021 @default.
• W1834341727 countsByYear W18343417272022 @default.
• W1834341727 crossrefType "journal-article" @default.
• W1834341727 hasAuthorship W1834341727A5011111764 @default.
• W1834341727 hasAuthorship W1834341727A5015608013 @default.
• W1834341727 hasAuthorship W1834341727A5036798090 @default.
• W1834341727 hasAuthorship W1834341727A5046991927 @default.
• W1834341727 hasAuthorship W1834341727A5061464184 @default.
• W1834341727 hasAuthorship W1834341727A5067414076 @default.
• W1834341727 hasAuthorship W1834341727A5076592943 @default.
• W1834341727 hasAuthorship W1834341727A5087679577 @default.
• W1834341727 hasBestOaLocation W18343417272 @default.
• W1834341727 hasConcept C112705442 @default.
• W1834341727 hasConcept C126322002 @default.
• W1834341727 hasConcept C142724271 @default.
• W1834341727 hasConcept C197934379 @default.
• W1834341727 hasConcept C198451711 @default.
• W1834341727 hasConcept C204787440 @default.
• W1834341727 hasConcept C22979827 @default.
• W1834341727 hasConcept C27081682 @default.
• W1834341727 hasConcept C2776164576 @default.
• W1834341727 hasConcept C2778375690 @default.
• W1834341727 hasConcept C2779286237 @default.
• W1834341727 hasConcept C42219234 @default.
• W1834341727 hasConcept C71924100 @default.
• W1834341727 hasConcept C90924648 @default.
• W1834341727 hasConcept C98274493 @default.
• W1834341727 hasConceptScore W1834341727C112705442 @default.
• W1834341727 hasConceptScore W1834341727C126322002 @default.
• W1834341727 hasConceptScore W1834341727C142724271 @default.
• W1834341727 hasConceptScore W1834341727C197934379 @default.
• W1834341727 hasConceptScore W1834341727C198451711 @default.
• W1834341727 hasConceptScore W1834341727C204787440 @default.
• W1834341727 hasConceptScore W1834341727C22979827 @default.
• W1834341727 hasConceptScore W1834341727C27081682 @default.
• W1834341727 hasConceptScore W1834341727C2776164576 @default.
• W1834341727 hasConceptScore W1834341727C2778375690 @default.
• W1834341727 hasConceptScore W1834341727C2779286237 @default.
• W1834341727 hasConceptScore W1834341727C42219234 @default.
• W1834341727 hasConceptScore W1834341727C71924100 @default.
• W1834341727 hasConceptScore W1834341727C90924648 @default.
• W1834341727 hasConceptScore W1834341727C98274493 @default.
• W1834341727 hasIssue "1" @default.
• W1834341727 hasLocation W18343417271 @default.
• W1834341727 hasLocation W18343417272 @default.
• W1834341727 hasLocation W18343417273 @default.
• W1834341727 hasLocation W18343417274 @default.
• W1834341727 hasOpenAccess W1834341727 @default.
• W1834341727 hasPrimaryLocation W18343417271 @default.
• W1834341727 hasRelatedWork W1966031956 @default.
• W1834341727 hasRelatedWork W2074207917 @default.
• W1834341727 hasRelatedWork W2090906690 @default.

• next